Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation | MicrobiomeTrials← Back to trialsNCT02669251
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2016-04-28Est. Completion: 2027-12-01
Enrollment target: 14 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Pancreatitis, Chronic; Diabetes; Transplant
Patients with severe chronic pancreatitis may be candidates to have their pancreas removed and their islets transplanted…
Minneapolis, United StatesCompleted Jul 1, 2023
Acute Leukemia in RemissionMyelodysplastic SyndromesMyeloproliferative SyndromeHodgkin LymphomaLymphoma, Non-HodgkinMyelomaChronic Lymphocytic Leukemia
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic h…
Amiens, FranceEst. completion May 2030